See the DrugPatentWatch profile for Praluent
What is Praluent (alirocumab) used for?
Praluent (alirocumab) is an injection used to lower low-density lipoprotein (LDL) cholesterol. It’s prescribed for people who need additional LDL lowering despite lifestyle changes and, when appropriate, other cholesterol medications.
How is Praluent injection given (dose, schedule, and where to inject)?
Praluent is given as a subcutaneous (under-the-skin) injection. Patients typically inject it themselves using the pen or prefilled syringe (depending on the product they’re prescribed). The dosing schedule depends on the prescribed dose and the patient’s treatment plan.
What happens if you miss a dose of Praluent?
If a scheduled dose is missed, the next step depends on how much time has passed since the missed dose. Patients should follow the specific instructions in their prescribing information or the directions given by their clinician to decide when to take the next dose.
What side effects do people report with Praluent injections?
Common side effects associated with Praluent generally include reactions at the injection site. As with other medicines, other adverse reactions can occur, and patients should seek medical advice if they develop concerning symptoms.
How does Praluent compare with other cholesterol injections (like Repatha)?
Praluent and other PCSK9 inhibitors are used to lower LDL cholesterol by increasing LDL clearance. Patients often compare them based on dosing convenience, insurance coverage, and out-of-pocket cost, since their cholesterol-lowering purpose is similar.
Who makes Praluent and is it protected by patents?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including medicines like Praluent. If you’re researching market exclusivity or potential competition, DrugPatentWatch.com is one place to check the latest status: https://www.drugpatentwatch.com/
Important safety and practical patient questions
Patients often ask about training for self-injection, how to store Praluent, and when to call a clinician for injection reactions or new symptoms. Those details are set out in the product’s prescribing information and should match what the patient receives from their healthcare team.
Sources
- https://www.drugpatentwatch.com/